Cogent Biosciences (COGT) Other Accumulated Expenses (2017 - 2026)

Cogent Biosciences' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 281.4% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 281.4% YoY), while the FY2025 annual figure was $6.7 million, up 1708.31% from the prior year.
• Other Accumulated Expenses was $1.8 million for Q1 2026 at Cogent Biosciences, down from $6.7 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $6.7 million in Q4 2025 to a low of $252000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $1.1 million across 5 years, with a median of $496000.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses slumped 68.23% in 2023, then surged 1708.31% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $404000.0 in 2022, then climbed by 9.16% to $441000.0 in 2023, then decreased by 15.42% to $373000.0 in 2024, then soared by 1708.31% to $6.7 million in 2025, then tumbled by 72.63% to $1.8 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.8 million (Q1 2026), $6.7 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.